Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Recruiting

Phase 1

Phase 2

GlumetinibAssessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Sponsor:

Haihe Biopharma Co., Ltd.

Code:

NCT04270591

Conditions

C-Met Exon 14 Mutation

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Glumetinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-28. This information was provided to ClinicalTrials.gov by Haihe Biopharma Co., Ltd. on 2022-08-01.